Kezar Life Sciences

$3.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.17 (-4.10%) As of 2:07 PM EDT today
-$0.17 (-4.10%) Today

Why Robinhood?

You can buy or sell KZR and other stocks, options, ETFs, and crypto commission-free!

About KZR

Kezar Life Sciences, Inc. Common Stock, also called Kezar Life Sciences, is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. Read More The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Employees
24
Headquarters
South San Francisco, California
Founded
2015
Market Cap
79.42M
Price-Earnings Ratio
Dividend Yield
Average Volume
67.15K
High Today
$4.48
Low Today
$3.95
Open Price
$4.13
Volume
32.88K
52 Week High
$36.33
52 Week Low
$3.95

Collections

KZR Earnings

-$0.49
-$0.43
-$0.36
-$0.30
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.